The approval of disease-modifying therapies for early, symptomatic Alzheimer’s disease is raising hope for patients and caregivers. And promising new therapeutic and diagnostic capabilities are expected in the next five … Read More
Journal of Managed Care + Specialty Pharmacy: 10-year projection of pediatric onset rare disease therapy approvals, treated patients, and list price revenues
New research in Journal of Managed Care + Specialty Pharmacy (JMCP) provides insights into the future landscape of treatments for rare diseases that present in childhood, offering a balanced picture … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
- Page 2 of 2
- 1
- 2